乳腺癌患者接受大分割区域淋巴结放疗时放射性食管炎的剂量-体积预测因素
本研究纳入298例乳腺癌术后接受大分割区域淋巴结放疗的患者,评估放射性食管炎的发生率及剂量-体积预测因素。2级和3级放射性食管炎发生率分别为40.9%(122/298)和0.3%(1/298)。食管RV25阈值20%和AV35阈值0.27 mL为2级及以上放射性食管炎的最佳剂量-体积预测指标。
要点
- 2级放射性食管炎发生率为40.9%(122/298),3级为0.3%(1/298)。
- 食管RV20-RV40和AV35-AV40与2级及以上放射性食管炎风险显著相关。
- RV25阈值20%时,两组2级及以上放射性食管炎发生率分别为35.9%和60.9%(P=.04)。
核心结论
- 放射性食管炎在乳腺癌大分割区域淋巴结放疗患者中常见。
- 维持食管上部V25低于20%且V35低于0.27 mL可能降低放射性食管炎风险。
研究设计与样本
- 纳入2020年5月8日至2022年1月5日期间298例乳腺癌术后接受胸壁、锁骨上/锁骨下窝、腋窝II站和/或内乳链调强放疗的患者,处方剂量43.5 Gy分15次。
- 放疗期间每周评估放射性食管炎,放疗后1周、2周、3个月和6个月评估,按美国国家癌症研究所不良事件通用术语标准3.0版分级。
- 食管从环状软骨下缘水平勾画至主动脉弓下缘,评估食管总体积、平均剂量、最大剂量及至少接受5至45 Gy(以5 Gy递增)的相对体积(RV5-RV45)和绝对体积(AV5-AV45)。
- 采用单因素和多因素logistic回归分析确定放射性食管炎危险因素,并获得受试者工作特征曲线以确定食管剂量学参数阈值。
主要发现
- 2级放射性食管炎发生率为40.9%(122/298),3级为0.3%(1/298),未观察到4级或5级放射性食管炎。
- 调整肿瘤侧别和内乳淋巴结照射后,食管RV20-RV40和AV35-AV40与2级及以上放射性食管炎风险显著相关。
- RV25和AV35为2级及以上放射性食管炎的最佳剂量-体积预测指标,RV25阈值20%时两组发生率分别为35.9%和60.9%(P=.04),AV35阈值0.27 mL时两组发生率分别为31.0%和54.6%(P=.04)。
关键数值与推荐
- 处方剂量为43.5 Gy分15次。
- 2级放射性食管炎发生率为40.9%(122/298),3级为0.3%(1/298)。
- RV25阈值20%时,2级及以上放射性食管炎发生率分别为35.9%和60.9%(P=.04)。
- AV35阈值0.27 mL时,2级及以上放射性食管炎发生率分别为31.0%和54.6%(P=.04)。
临床怎么用
- 维持食管上部V25低于20%且V35低于0.27 mL可能降低放射性食管炎风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our objective was to assess the incidence and dose-volume predictors of radiation esophagitis (RE) in patients with breast cancer undergoing hypofractionated regional nodal irradiation. METHODS AND MATERIALS: Eligible patients who received intensity modulated radiation therapy (RT) at the chest wall, the supraclavicular/infraclavicular fossa, level II axilla, and/or the internal mammary chain after mastectomy were included. The prescribed dose was 43.5 Gy in 15 fractions. RE was evaluated weekly during RT and at 1 and 2 weeks, followed by 3 and 6 months after RT, and was graded according to National Cancer Institute Common Toxicity Criteria for Adverse Events, version 3.0. The esophagus was contoured from the lower border level of the cricoid cartilage to the lower margin of the aortic arch. Esophageal total volume, mean dose, maximum dose, and the relative volumes (RV) and absolute volumes (AV) receiving at least 5 to 45 Gy by 5-Gy increments (RV5-RV45 and AV5-AV45) were evaluated. Univariable and multivariable logistic regression analyses were performed to determine risk factors for RE, and receiver operating characteristic curves were obtained to identify the thresholds of esophageal dosimetric parameters. RESULTS: In total, 298 patients were included between May 8, 2020, and January 5, 2022 (minimum post-RT follow-up: 6 months). Grade 2 and 3 RE incidence was 40.9% (122/298) and 0.3% (1/298), respectively. No grade 4 or 5 RE was observed. Esophageal RV20-RV40 and AV35-AV40 were significantly associated with the risk of grade ≥2 RE after adjusting for tumor laterality and internal mammary nodal irradiation. RV25 and AV35 were optimum dose-volume predictors for grade ≥2 RE at thresholds 20% for RV25 (35.9% vs 60.9%; P = .04) and 0.27 mL for AV35 (31.0% vs 54.6%; P = .04). CONCLUSIONS: RE is common in patients with breast cancer undergoing hypofractionated regional nodal irradiation. Maintaining the upper esophageal V25 at <20% and V35 at <0.27 mL may decrease the risk of RE.
引用
- Wang DQ, Zhang N, Dong LH, et al. Dose-Volume Predictors for Radiation Esophagitis in Patients With Breast Cancer Undergoing Hypofractionated Regional Nodal Radiation Therapy. Int J Radiat Oncol Biol Phys. 2023. PMID: 37001764. doi:10.1016/j.ijrobp.2023.03.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。